Biocad goals go beyond putting Russian biotech on the map

Roman Ivanov, vice president of research and development (R&D) at Biocad, describes his company’s current transition as going from being a local biosimilar player in its native Russia, to a global mid-sized biopharmaceutical player, in an interview with The Pharma Letter's Guy Martin.

When he talks about the privately-held company’s already-approved monoclonal antibody (MAb) biosimilars, the impact they have had on drug access in emerging markets, as well as Biocad’s pipeline of around 40 of its own drug candidates and ambitions to target regulated markets, it is clear that the company could have a major impact internationally.

"Checkpoint inhibitors have made a revolution in terms of treatment of cancer, but the enormous cost of those drugs is prohibitive in emerging markets, but also for developed markets"